Oxandrin

Oxandrin is a brand name of oxandrolone, approved by the FDA in the following formulation(s):

OXANDRIN (oxandrolone - tablet; oral)

• 
  Manufacturer: SAVIENT PHARMS
  
  Approved Prior to Jan 1, 1982
  
  Strength(s): 2.5MG ^[AB]


• 
  Manufacturer: SAVIENT PHARMS
  
  Approval date: November 5, 2001
  
  Strength(s): 10MG ^[RLD][AB]

Has a generic version of Oxandrin been approved?

A generic version of Oxandrin has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Oxandrin and have been approved by the FDA:

oxandrolone tablet; oral

• 
  Manufacturer: PAR PHARM
  
  Approval date: June 22, 2007
  
  Strength(s): 10MG ^[AB], 2.5MG ^[AB]


• 
  Manufacturer: SANDOZ
  
  Approval date: December 1, 2006
  
  Strength(s): 10MG ^[AB], 2.5MG ^[AB]


• 
  Manufacturer: UPSHER SMITH
  
  Approval date: December 1, 2006
  
  Strength(s): 2.5MG ^[AB]


• 
  Manufacturer: UPSHER SMITH
  
  Approval date: March 22, 2007
  
  Strength(s): 10MG ^[AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Oxandrin. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Use of oxandrolone in the treatment of chronic obstructive pulmonary disease
  Patent 5,872,147
  Issued: February 16, 1999
  Inventor(s): Bowen; Robert E.
  Assignee(s): Bio-Technology General Corp.
  The subject invention provides a method of treating a symptom associated with chronic obstructive pulmonary disease in a patient suffering from chronic obstructive pulmonary disease which comprises administering a therapeutically effective amount of an oxandrolone to the patient. The subject invention further provides a method of improving functional capacity and/or pulmonary function in a patient suffering from chronic obstructive pulmonary disease which comprises administering a therapeutically effective amount of an oxandrolone to the patient.
  
  Patent expiration dates:
  
  
  • December 5, 2017
    
    ✓ 
    Patent use: TO PROMOTE WEIGHT GAIN AFTER WEIGHT LOSS IN CERTAIN TYPES OF PATIENTS
  
  



• 
  Method for ameliorating muscle weakness/wasting in a patient infected with human immunodeficiency virus-type 1
  Patent 6,090,799
  Issued: July 18, 2000
  Inventor(s): Berger; Joseph R.
  Assignee(s): BTG Pharmaceuticals Corp.
  A method for attenuating the HIV-associated myopathy and muscle wasting associated with infection by human immunodeficiency virus-Type 1. Administration of oxandrolone in a daily dosage of about 2.5 to about 20 milligrams is described.
  
  Patent expiration dates:
  
  
  • July 18, 2017
    
    ✓ 
    Patent use: TO PROMOTE WEIGHT GAIN AFTER WEIGHT LOSS IN CERTAIN TYPES OF PATIENTS
  
  



• 
  Use of oxandrolone in the treatment of burns an other wounds
  Patent 6,576,659
  Issued: June 10, 2003
  Inventor(s): Don; Fishbein
  Assignee(s): Bio-Technology General Corp.
  The subject invention provides a method of treating burn-induced weight loss in a burn patient which comprises administering a therapeutically effective amount of an oxandrolone to the patient. The invention also provides a method of treating a wound in a patient suffering from a wound which comprises administering a therapeutically effective amount of an oxandrolone to the patient. The subject invention further provides a method of treating burn-induced weight loss in a burn patient which comprises administering a therapeutically effective amount of an oxandrolone in conjunction with a protein supplement to the patient.
  
  Patent expiration dates:
  
  
  • December 5, 2017
    
    ✓ 
    Patent use: TO PROMOTE WEIGHT GAIN AFTER WEIGHT LOSS IN CERTAIN TYPES OF PATIENTS
  
  



• 
  Method for ameliorating muscle weakness/wasting in a patient infected with human immunodeficiency virus-type 1
  Patent 6,670,351
  Issued: December 30, 2003
  Inventor(s): Joseph R.; Berger
  Assignee(s): Bio-Technology General Corporation
  A method for attenuating the HIV-associated myopathy and muscle wasting associated with infection by human immunodeficiency virus-Type 1. Administration of oxandrolone in a daily dosage of about 2.5 to about 20 milligrams is described.
  
  Patent expiration dates:
  
  
  • October 20, 2012
    
    ✓ 
    Patent use: TO PROMOTE WEIGHT GAIN AFTER WEIGHT LOSS IN CERTAIN TYPES OF PATIENTS
  
  



• 
  Use of oxandrolone in the treatment of burns and other wounds
  Patent 6,828,313
  Issued: December 7, 2004
  Inventor(s): Don; Fishbein
  Assignee(s): Savient Pharmaceuticals, Inc.
  The subject invention provides a method of treating burn-induced weight loss in a burn patient which comprises administering a therapeutically effective amount of an oxandrolone to the patient. The invention also provides a method of treating a wound in a patient suffering from a wound which comprises administering a therapeutically effective amount of an oxandrolone to the patient. The subject invention further provides a method of treating burn-induced weight loss in a burn patient which comprises administering a therapeutically effective amount of an oxandrolone in conjunction with a protein supplement to the patient.
  
  Patent expiration dates:
  
  
  • December 5, 2017
    
    ✓ 
    Patent use: TO PROMOTE WEIGHT GAIN AFTER WEIGHT LOSS IN CERTAIN TYPES OF PATIENTS
  
  

See also...

• Oxandrin Consumer Information (Wolters Kluwer)
• Oxandrin Consumer Information (Cerner Multum)
• Oxandrin AHFS DI Monographs (ASHP)
• Oxandrolone Consumer Information (Wolters Kluwer)
• Oxandrolone Consumer Information (Cerner Multum)
• Oxandrolone AHFS DI Monographs (ASHP)